Who is sponsoring NCT00723749?

NCT00723749 is sponsored by Indivior Inc..

What condition does NCT00723749 study?

NCT00723749 studies Opioid-Related Disorders, Opiate Dependence, Drug Abuse.

What drugs are being tested in NCT00723749?

Interventions: Buprenorphine/Naloxone.

What is the status of NCT00723749?

NCT00723749 is currently COMPLETED.

Last reviewed 2012-04-26 · How we verify

Post-marketing Surveillance Study (Paper-AWB) for GPs and Clinics: Treatment of Opioid-dependent Patients With SUBOXONE® 2 mg / 8 mg Sublingual Tablets - Acceptability and Safety Data From a Real Life Scenario.

NCT00723749 COMPLETED Results posted

The aim of this post marketing surveillance study is to investigate the retention rate after 12 months of drug dependence treatment with SUBOXONE® (buprenorphine plus naloxone) of opioid dependent patients under real life conditions.

Details

Lead sponsor	Indivior Inc.
Status	COMPLETED
Enrolment	384
Start date	2008-03
Completion	2010-12

Conditions

Opioid-Related Disorders
Opiate Dependence
Drug Abuse

Interventions

Buprenorphine/Naloxone

Primary outcomes

Retention Rate After 12 Months of Treatment With Suboxone — 12 months
The primary aim of the SUBOXONE® NIS was to document the 12-month retention rate for at least N = 300 subjects with opioid dependence in a real-life scenario in at least N = 70 sites throughout Germany.